Home Cart Sign in  
Chemical Structure| 87239-81-4 Chemical Structure| 87239-81-4

Structure of Cefpodoxime Proxetil
CAS No.: 87239-81-4

Chemical Structure| 87239-81-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cefpodoxime Proxetil is active against most gram-positive and gram-negative organisms that can be used to treat acute otitis media, pharyngitis. It is a third generation cephalosporin.

Synonyms: CS-807; U-76,252

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cefpodoxime Proxetil

CAS No. :87239-81-4
Formula : C21H27N5O9S2
M.W : 557.60
SMILES Code : O=C(C(N12)=C(COC)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)OC(OC(OC(C)C)=O)C
Synonyms :
CS-807; U-76,252
MDL No. :MFCD00865088

Safety of Cefpodoxime Proxetil

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02829060 Nephrolithiasis ... More >> Urinary Tract Infection (UTI) Sepsis Less << Not Applicable Recruiting January 2019 United States, California ... More >> University of California San Diego Recruiting San Diego, California, United States, 92101 Contact: Roger L Sur, MD    619-543-2628    rlsur@ucsd.edu    Contact: Joel E Abbott, DO    619-543-2628    jabbott@westernu.edu    Sub-Investigator: Seth K Bechis, MD Less <<
NCT01502878 Nut Allergy Not Applicable Completed - Finland ... More >> Helsinki University Central Hospital, Skin and Allergy Hospital Helsinki, Finland, 00029 Helsinki University Central Hospital, Skin and Allergy Hospital Helsinki, Finland, 160 Less <<
NCT02099240 Osteomyelitis Early Phase 1 Recruiting September 2019 United States, Kentucky ... More >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD Less <<
NCT00644696 Neuroblastoma Phase 1 Completed - United States, Michigan ... More >> The University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 Less <<
NCT01511107 Acute Otitis Media Phase 2 Terminated(The primary objecti... More >>ve of the study was met.) Less << - United States, Kentucky ... More >> Kentucky Pediatric/Adult Research Bardstown, Kentucky, United States, 40004 United States, Pennsylvania Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States, 15224 Less <<
NCT00222443 Lymphomas Tum... More >>ors Less << Phase 1 Completed - United States, Oklahoma ... More >> Oklahoma University Health Sciences Center-Jimmy Everest Center Oklahoma City, Oklahoma, United States, 73104 Less <<
NCT00494520 Anomia Aphasi... More >>a Traumatic Brain Injury Cerebrovascular Accident Less << Not Applicable Completed - United States, District of Col... More >>umbia Georgetown University Medical Center Washington, D.C., District of Columbia, United States, 20057 Less <<
NCT02624882 Blistering Distal Dactylitis Not Applicable Completed - France ... More >> CHI Creteil Créteil, France, 94000 Less <<
NCT00786669 Solid Tumor Phase 1 Completed - United States, Ohio ... More >> Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Less <<
NCT00186979 Solid Tumors Phase 1 Completed - United States, Tennessee ... More >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 Less <<
NCT03098485 Microbiota An... More >>ti-bacterial Agents Less << Not Applicable Active, not recruiting June 30, 2019 United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less <<
NCT03729258 Sinusitis Sin... More >>usitis, Acute Rhinosinusitis Rhinosinusitis Acute Sinus Infection Less << Phase 3 Not yet recruiting September 1, 2019 Turkey ... More >> Bakırköy Dr. Sadi Konuk Training and Research Hospital Not yet recruiting Istanbul, Turkey Contact: İbrahim Sayın, Assoc Prof Dr          Contact       dribrahimsayin@yahoo.com Less <<
NCT00194532 Urinary Tract Infection Not Applicable Completed - United States, Florida ... More >> University of Miami Miller School of Medicine Miami, Florida, United States, 33136 United States, Washington University of Washington Seattle, Washington, United States, 98195 Less <<
NCT01511107 - Terminated(The primary objecti... More >>ve of the study was met.) Less << - -
NCT03491748 Healthy Volunteers Phase 1 Recruiting May 2019 Australia, Victoria ... More >> Nucleus Network Recruiting Melbourne, Victoria, Australia, 3004 Less <<
NCT00143533 Neoplasm Diar... More >>rhea Less << Phase 1 Completed - United States, Tennessee ... More >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 Less <<
NCT00194532 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.79mL

0.36mL

0.18mL

8.97mL

1.79mL

0.90mL

17.93mL

3.59mL

1.79mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories